Expert Consensus on Clinical Standardized Application of HFNC in Adults

0
0
0

Expert Consensus on Clinical Standardized Application of High-Flow Nasal Cannula Oxygen Therapy in Adults

High-flow nasal cannula oxygen therapy (HFNC) represents a significant advancement in respiratory support technology, offering a unique combination of comfort and efficacy for adult patients. This consensus document outlines standardized clinical practices for HFNC application, addressing its mechanisms, indications, contraindications, operational protocols, and monitoring strategies.

Technical Components and Physiological Mechanisms

HFNC systems comprise four primary components: an air-oxygen blender, an active humidifier, a high-flow nasal cannula, and an inspiratory circuit. These components work synergistically to deliver heated (31–37°C), humidified gas at flow rates ranging from 8 to 80 L/min, with adjustable oxygen concentrations (21–100%). The technology’s efficacy stems from multiple physiological effects:

  1. Positive End-Expiratory Pressure (PEEP): HFNC generates a low-level PEEP (exact value dependent on flow rate and patient anatomy), which aids in alveolar recruitment and reduces atelectasis.
  2. Dead Space Washout: High-flow gases efficiently flush the anatomical dead space of the upper airways, reducing CO₂ rebreathing and improving ventilation efficiency.
  3. Mucociliary Function Preservation: Optimal temperature and humidity levels maintain mucociliary clearance, preventing mucosal drying and secretion retention.
  4. Reduced Work of Breathing: By minimizing upper airway resistance and providing consistent inspiratory flow, HFNC decreases the patient’s respiratory effort.

Indications and Contraindications

Indications

HFNC is recommended for patients with the following conditions:

  • Mild-to-Moderate Type I Respiratory Failure: Defined as a PaO₂/FiO₂ ratio between 100 mmHg and 300 mmHg.
  • Mild Respiratory Distress: Respiratory rate >24 breaths/minute without severe ventilatory compromise.
  • Mild Ventilatory Dysfunction: Arterial pH ≥7.30, indicating compensated respiratory acidosis.
  • Intolerance to Conventional Oxygen Therapy or Non-Invasive Ventilation (NIV): Patients who cannot tolerate interfaces like masks or require higher flow rates.

Relative Contraindications

  • Severe Type I Respiratory Failure: PaO₂/FiO₂ <100 mmHg.
  • Significant Ventilatory Dysfunction: pH <7.30 or paradoxical breathing patterns.
  • High Aspiration Risk: Poor airway protection due to altered mental status or impaired swallowing.
  • Hemodynamic Instability: Patients requiring vasoactive medications.
  • Anatomical Limitations: Facial trauma, recent upper airway surgery, or severe nasal obstruction.

Absolute Contraindications

  • Cardiopulmonary Arrest: Immediate endotracheal intubation and mechanical ventilation are required.
  • Coma or Absent Spontaneous Breathing: Lack of respiratory drive.
  • Very Severe Hypoxemia: PaO₂/FiO₂ <60 mmHg.
  • Severe Acidosis: pH <7.25.

Clinical Application Pathways

Acute Respiratory Failure Management (Figure 1)

  1. Initial Assessment: Evaluate oxygenation (PaO₂/FiO₂), respiratory rate, and acid-base status.
  2. HFNC Initiation Criteria:
    • PaO₂/FiO₂ ≥100 mmHg with FiO₂ ≥0.5.
    • Respiratory rate >24 breaths/min and pH ≥7.30.
  3. Escalation to Invasive Ventilation:
    • If PaO₂/FiO₂ remains <100 mmHg after 1–2 hours.
    • Worsening acidosis (pH 35 breaths/min.

Post-Extubation Support (Figure 2)

  1. Low-Risk Patients:
    • Defined as age <65 years, APACHE II score <12, BMI <30 kg/m², patent airway, and absence of chronic comorbidities.
    • HFNC reduces reintubation rates compared to conventional oxygen therapy.
  2. High-Risk Patients:
    • Age ≥65 years, heart failure, APACHE II ≥12, or mechanical ventilation >7 days.
    • Use HFNC prophylactically to mitigate post-extubation respiratory failure.

Operational Guidelines

Parameter Settings

  • Flow Rate: Initiate at 35–45 L/min and titrate based on patient tolerance and oxygenation needs.
  • FiO₂: Start at 0.4–0.6 and adjust to maintain SpO₂ ≥92%.
  • Temperature: Set at 34–37°C for optimal comfort and humidification.

Monitoring and Assessment

  • Hourly Checks: Monitor respiratory rate, SpO₂, and work of breathing during the first 6 hours.
  • Arterial Blood Gas (ABG) Analysis: Perform at baseline and 1–2 hours post-initiation to assess PaO₂/FiO₂ and pH.
  • Discontinuation Criteria: Transition to conventional oxygen therapy if PaO₂/FiO₂ >300 mmHg and respiratory rate <20 breaths/min.

Safety and Complications

  • Nasal Discomfort or Dryness: Adjust temperature and humidity settings.
  • Barotrauma Risk: Rare but possible with flow rates >60 L/min in patients with air trapping.
  • CO₂ Retention: Monitor PaCO₂ in patients with chronic hypercapnia.

Standardization and Evidence Grading

This consensus employs a three-tiered evidence hierarchy:

  • Level I: High-quality RCTs, systematic reviews, and guidelines.
  • Level II: Observational studies or RCTs with methodological limitations.
  • Level III: Case reports and expert opinions.

Recommendations prioritize Level I evidence, such as studies demonstrating HFNC’s superiority over NIV in post-extubation care for low-risk patients.

Conclusion

HFNC offers a versatile, patient-centered approach to respiratory support, balancing efficacy with tolerability. By adhering to standardized protocols for patient selection, parameter adjustment, and monitoring, clinicians can optimize outcomes in acute and post-extubation settings. Future research should address gaps in long-term efficacy and cost-effectiveness.

doi.org/10.1097/CM9.0000000000000769

Was this helpful?

0 / 0